Pronostics to Supply Next Generation Diagnostics for Autoimmune Disease to University of Birmingham
News Jul 16, 2008
Pronostics Ltd, developer and manufacturer of next generation multiplexed diagnostics for healthcare providers and the pharmaceutical industry, has signed a deal with University of Birmingham Medical School (UBMS) to provide next generation autoimmune testing services for its clinical immunology service.
As part of the deal, Pronostics will provide UBMS clinical immunology service with its fully automated UltraPlex™ system and ANA Assay for the diagnosis of autoimmune disease. This follows an independent trial at UBMS in 2007 which compared Pronostics’ UltraPlex™ ANA assay with existing testing methods employed.
The UltraPlex™ solution eliminates the possibility of subjective errors, removes non-specific positive results and focuses on clinically significant results, with known disease association. Its introduction will also significantly reduce test turn-a-round times.
The UltraPlex™ ANA assay, consists of 11 tests in one, providing valuable time and cost savings compared to serial testing approaches or current multiplexing methods. It allows hospitals and laboratories to perform fully automated tests on patient samples and gives both quantitative and qualitative results for antibodies in autoimmune diseases.
UltraPlex™ is a digital multiplexing solution which enables tens to hundreds of tests to be performed simultaneously in a single assay using a microscopic bar coding system. Over the coming year Pronostics will be launching assays in the cardiovascular and cancer disease areas to supplement its autoimmune range which currently includes ANA, Coeliac and Thyroid assays.
Timothy Plant, Laboratory Manager for UBMS clinical immunology services said: ‘’We are very pleased to have signed this deal with Pronostics and look forward to enjoying the benefits the UltraPlex™ platform has to offer’’.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.